Entero Issuance Of Capital Stock from 2010 to 2024
| ENTO Stock | 0.60 0.25 71.43% |
Issuance Of Capital Stock | First Reported 2010-12-31 | Previous Quarter 15.8 M | Current Value 18.6 M | Quarterly Volatility 6.8 M |
Check Entero Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entero Therapeutics,'s main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 3.5 K or Depreciation And Amortization of 27.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.34. Entero financial statements analysis is a perfect complement when working with Entero Therapeutics, Valuation or Volatility modules.
Entero | Issuance Of Capital Stock |
Latest Entero Therapeutics,'s Issuance Of Capital Stock Growth Pattern
Below is the plot of the Issuance Of Capital Stock of Entero Therapeutics, over the last few years. It is Entero Therapeutics,'s Issuance Of Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entero Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Issuance Of Capital Stock | 10 Years Trend |
|
Issuance Of Capital Stock |
| Timeline |
Entero Issuance Of Capital Stock Regression Statistics
| Arithmetic Mean | 16,899,870 | |
| Geometric Mean | 16,107,748 | |
| Coefficient Of Variation | 40.27 | |
| Mean Deviation | 4,122,923 | |
| Median | 14,186,088 | |
| Standard Deviation | 6,804,991 | |
| Sample Variance | 46.3T | |
| Range | 25.6M | |
| R-Value | 0.44 | |
| Mean Square Error | 40.1T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | 672,984 | |
| Total Sum of Squares | 648.3T |
Entero Issuance Of Capital Stock History
About Entero Therapeutics, Financial Statements
Entero Therapeutics, investors utilize fundamental indicators, such as Issuance Of Capital Stock, to predict how Entero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Issuance Of Capital Stock | 15.8 M | 18.6 M |
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Entero Stock
Moving against Entero Stock
| 0.83 | BMY | Bristol Myers Squibb | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.75 | ZTS | Zoetis Inc | PairCorr |
| 0.7 | GILD | Gilead Sciences | PairCorr |
| 0.59 | FHTX | Foghorn Therapeutics | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Entero Stock
When determining whether Entero Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Entero Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Entero Therapeutics, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Entero Therapeutics, Stock:Check out the analysis of Entero Therapeutics, Correlation against competitors. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.